HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CP-673,451

is a potent inhibitor of platelet-derived growth factor beta-receptor (PDGFR-beta) kinase; structure in first source

Also Known As:

CP-673451

Networked: 5 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzimidazoles: 245
      - CP-673,451: 5
    - Quinolines: 146
      - CP-673,451: 5

Experts

1.	Chen, Xianguo: 1 article (10/2021)
2.	Chen, Xu: 1 article (10/2021)
3.	Hu, Zhongdong: 1 article (10/2021)
4.	Huang, Fuqiang: 1 article (10/2021)
5.	Jin, Fuquan: 1 article (10/2021)
6.	Ni, Zhaofei: 1 article (10/2021)
7.	Ren, Min: 1 article (10/2021)
8.	Wan, Xiaofeng: 1 article (10/2021)
9.	Wang, Yani: 1 article (10/2021)
10.	Wu, Yuncui: 1 article (10/2021)

Related Diseases

1.	Neoplasms (Cancer) 02/01/2005 - "The antitumor efficacy of CP-673,451 was evaluated in a number of human tumor xenografts grown s.c. " 01/01/2014 - "Furthermore, CP-673451 is effective at suppressing NSCLC tumor growth in vivo. " 10/01/2021 - "Lastly, combination treatment with the AKT inhibitor MK-2206 and the PDGFR inhibitor CP-673451 displayed synergistic anti-tumor effects. " 02/01/2005 - "Inhibition of PDGFR-beta phosphorylation in tumors correlates with plasma and tumor levels of CP-673,451. " 02/01/2005 - "Multiple models have been used to evaluate in vivo activity of CP-673,451 and to understand the pharmacology of PDGFR-beta inhibition and the effect on tumor growth. "
2.	Lung Neoplasms (Lung Cancer) 01/01/2014 - "CP-673451, a platelet-derived growth-factor receptor inhibitor, suppresses lung cancer cell proliferation and migration."
3.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2014 - "Herein, we investigate the anticancer activities of CP-673451, a potent selective inhibitor of PDGFR kinase, in non-small-cell lung cancer (NSCLC) therapy. "
4.	Urinary Bladder Neoplasms (Bladder Cancer) 01/01/2019 - "Furthermore, blocking the YAP/TEAD1/PDGF-BB/PDGFR loop with verteporfin or CP-673451 inhibited the cis-platinum resistance of OV6+ bladder cancer CSCs in an orthotopic bladder cancer model. "
5.	Cytokine Release Syndrome 10/01/2022 - "This suggests that CP-673451 may prevent septic death by inhibiting lymphocyte chemotaxis and alleviating "cytokine storm". "

Related Drugs and Biologics

1.	Becaplermin (PDGF-BB)
2.	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)
3.	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
4.	Phosphotransferases (Kinase)
5.	Cisplatin (Platino)
6.	Verteporfin (Visudyne)
7.	MK 2206

Related Therapies and Procedures

1.	Therapeutics